Aplastic Anemia Market to Witness Significant Growth by 2034, Fueled by Rising Prevalence and a Strong Pipeline | DelveInsight

The aplastic anemia treatment market is poised for significant growth, with key pharmaceutical companies including Novartis, Pfizer, Teva Pharmaceuticals, Kyowa Kirin, Regeneron Pharmaceuticals, Gamida Cell, and others leading therapeutic innovation in this rare hematologic disorder.
DelveInsight's "Aplastic Anemia Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides an in-depth understanding of aplastic anemia, including historical and forecasted epidemiology as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.

According to the comprehensive analysis, the aplastic anemia market, valued at approximately USD 270 million in 2023 across the 7MM, is projected to expand substantially through 2034, fueled by increasing disease incidence, growing uptake of existing therapies, and the anticipated launch of promising pipeline candidates.

Furthermore, the US currently dominates the aplastic anemia treatment landscape, accounting for approximately 70% of the market share in the 7MM, followed by Japan with the second-highest market value at approximately USD 35 million in 2023. Among European nations, Germany leads the market, with additional growth anticipated across all regions during the forecast period.

Download the Aplastic Anemia Market Forecast Report to understand which factors are driving the Aplastic Anemia market @ Aplastic Anemia Market Trends [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

DelveInsight's aplastic anemia epidemiological analysis reveals that Japan reported the highest aplastic anemia incident cases, contributing approximately 30% of cases across the 7MM in 2023. Notably, 56% of aplastic anemia cases were reported in individuals aged 60 and above, while 43% were below the age of 60.

Discover evolving trends in the Aplastic Anemia patient pool forecasts @ Aplastic Anemia Epidemiological Analysis [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The current aplastic anemia treatment varies based on patient age and disease severity. Hematopoietic stem cell transplantation (HSCT) remains the standard of care for patients under 40 years, while immunosuppressive therapy (IST) is preferred for those above 40 years. Novartis' PROMACTA / REVOLADE (eltrombopag) currently leads market revenue, followed by various immunosuppressive therapies. However, younger patients experience significantly better long-term survival compared to those aged 60 and above, highlighting a critical unmet need for improved management strategies in older populations.

The aplastic anemia therapeutic landscape is evolving with several marketed and emerging options. ALVAIZ (eltrombopag choline) from Teva Pharmaceuticals (NYSE: TEVA), an oral thrombopoietin receptor agonist that stimulates platelet production, approved in November 2023, represents an important treatment advancement. In Japan, Kyowa Kirin's ROMIPLATE has gained approval for patients showing inadequate response to conventional therapy.

The patent for PROMACTA (eltrombopag), a key treatment for aplastic anemia, is set to expire on July 13, 2025. This expiry will likely lead to the introduction of generic versions, which can reduce treatment costs and increase patient access. As Promacta is currently a leading therapy in the aplastic anemia market, the availability of generics is expected to intensify competition, lower prices, and potentially shift prescribing patterns.

Looking toward future market growth, promising pipeline candidates include REGN7257 from Regeneron Pharmaceuticals (NASDAQ: REGN), a gamma chain cytokine receptor antibody targeting the common gamma chain found in various interleukin receptors. Currently in Phase I/II clinical trials, this therapy aims to address T-cell-mediated pathogenesis in severe aplastic anemia patients who have relapsed after immunosuppressive therapy. Another noteworthy emerging therapy is OMISIRGE (omidubicel) by Gamida Cell (NASDAQ: GMDA), a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood.

In April 2025, CK0801, an allogeneic T regulatory (Treg) cell therapy manufactured by Cellenkos, received FDA Orphan Drug Designation for aplastic anemia, supporting its development as a novel treatment for this rare condition. A Phase III registration trial is planned for the second half of 2025, positioning CK0801 as a promising non-immunosuppressive option for aplastic anemia patients unresponsive to standard therapies.

Discover evolving trends in the Aplastic Anemia treatment landscape @ Aplastic Anemia Recent Developments [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Despite therapeutic advances, significant challenges remain in the aplastic anemia treatment landscape. Finding effective and well-tolerated treatments for patients who do not respond to standard therapies or who are unsuitable candidates for aggressive interventions continues to be problematic. Additionally, poor survival rates among older patients represent a substantial unmet medical need requiring innovative approaches.

Table of Contents

1. Key Insights

2. Executive Summary of Aplastic Anemia

3. Aplastic Anemia Competitive Intelligence

4. Aplastic Anemia: Market Overview at a Glance

5. Aplastic Anemia: Disease Background and Overview

6. Patient Journey

7. Aplastic Anemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Aplastic Anemia Unmet Needs

10. Key Endpoints of Aplastic Anemia Treatment

11. Aplastic Anemia Marketed Products

12. Aplastic Anemia Emerging Therapies

13. Aplastic Anemia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Aplastic Anemia

17. KOL Views

18. Aplastic Anemia Market Drivers

19. Aplastic Anemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports

Aplastic Anemia Pipeline Insight [https://www.delveinsight.com/sample-request/aplastic-anemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Aplastic Anemia Pipeline Insight provides comprehensive insights about the Aplastic Anemia pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Aplastic Anemia companies, including Gamida-Cell, Regeneron Pharmaceuticals, and BioLineRx, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=aplastic-anemia-market-to-witness-significant-growth-by-2034-fueled-by-rising-prevalence-and-a-strong-pipeline-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.